Karyopharm: Selinexor Shows Clinical Activity In Prostate Cancer

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, announced the presentation of clinical data from an ongoing Phase 1 clinical study for its lead product candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE compound, in patients with advanced solid tumors.

Data presented in patients with chemotherapy refractory, castrate-resistant prostate cancer or CRPC treated with single-agent Selinexor showed a 60 percent disease control rate with maximum prostate-specific antigen reduction ranging from 27 percent to 60 percent and duration of treatment up to 502 days.

Selinexor also demonstrated early signs of clinical activity in other solid tumor indications including head and neck squamous cell carcinoma and ovarian cancer.

Selinexor was shown to have manageable and predictable side effects, mainly nausea, fatigue and anorexia, which improve over time on treatment.

These data were presented at the 2014 Congress of the European Society for Medical Oncology, occurring September 26-30, in Madrid, Spain.